• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
71,947.55 -1,635.67
( -2.22%)
Global Indices
Nasdaq
45,242.12 54.47
(0.12%)
Dow Jones
6,365.58 -24.27
(-0.38%)
Hang Seng
51,264.29 -621.56
(-1.20%)
Nikkei 225
10,176.45 48.49
(0.48%)
Forex
USD-INR
94.53 0.44
(0.47%)
EUR-INR
108.77 0.13
(0.12%)
GBP-INR
125.32 -0.25
(-0.20%)
JPY-INR
0.59 0.00
(-0.02%)

EQUITY - MARKET SCREENER

ANG Lifesciences India Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
540694
INE236W01016
49.9768362
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
24.05
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

hindustan unilever ltd
Maruti Suzuki clocks total sales of 2.13 lakh units in Feb'26; exports jump 56% YoY
Mar 02,2026

Total domestic sales stood at 174,840 units during the period under review, marginally higher by 0.3% compared with 174,379 units last year.

Domestic passenger vehicle sales remained flat at 161,000 units (up 0.1% YoY) in February 2026, as gains in utility vehicle sales offset weakness in the entry level segments.

LCV volumes rose 15.5% to 3,130 units, while supplies to other OEMs declined 1.5% to 10,710 units in February 2026 over February 2025.

Exports rose sharply by 56.5% YoY to 39,155 units in February 2026, significantly outpacing overall growth and increasing their contribution to total volumes during the month.

In a separate filing, Maruti Suzuki India stated that the total production during February 2026 stood at 227,550 units, compared with 197,471 units in February 2025, registering a growth of 15.2% YoY.

Maruti Suzuki India is engaged in the manufacture, purchase, and sale of motor vehicles, components, and spare parts (automobiles).

The company reported a 4.08% YoY increase in net profit to Rs 3,879.1 crore in Q3 FY26, compared with Rs 3,726.9 crore in Q3 FY25, while revenue from operations rose 28.74% YoY to Rs 49,904.1 crore.

The scrip fell 1.82% to currently trade at Rs 14599.05 on the BSE.